A Phase 2 interventional study of LY3502970 and Placebo in Obesity and Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 35 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one is the 12th largest by enrollment, is the only one that started in 2021, is the only one in phase 2, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 272 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 58th largest by enrollment of the 117 interventional ones that give a count, is one of 8 that started in 2021, is one of 22 in phase 2, and was the 13th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Within 3 months prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
Drug: LY3502970
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
Drug: LY3502970
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Drug: LY3502970
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Drug: LY3502970
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Drug: LY3502970
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Drug: LY3502970
Participants received placebo administered orally once daily until 36 weeks.
Drug: Placebo
Administered orally
Administered orally
Percent Change From Baseline in Body Weight in LY3502970 and Placebo
Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Time frame: Baseline, Week 26
Percent Change From Baseline in Body Weight in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Time frame: Baseline, Week 36
Change From Baseline in Body Weight in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Time frame: Baseline, Week 26
Change From Baseline in Body Weight in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Time frame: Baseline, Week 36
Change From Baseline in Waist Circumference in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Time frame: Baseline, Week 26
Change From Baseline in Waist Circumference in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Time frame: Baseline, Week 36
Change From Baseline in BMI in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Time frame: Baseline, Week 26
Change From Baseline in BMI in LY3502970 and Placebo
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
Time frame: Baseline, Week 36
Percentage of Participants With >=5% Body Weight Loss
Percentage of participants with \>=5% body weight loss was reported.
Time frame: Week 26
Percentage of Participants With >=10% Body Weight Loss
Percentage of participants with \>=10% body weight loss was reported.
Time frame: Week 26
Percentage of Participants With >=5% Body Weight Loss
Percentage of participants with \>=5% body weight loss was reported.
Time frame: Week 36
Percentage of Participants With >=10% Body Weight Loss
Percentage of participants with \>=10% body weight loss was reported.
Time frame: Week 36
| Milestone | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg -1 LY3502970 | 36 mg -2 LY3502970 | 45 mg -1 LY3502970 | 45 mg -2 LY3502970 | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 50 | 53 | 29 | 29 | 31 | 30 | 50 |
| Completed | 44 | 46 | 27 | 24 | 23 | 28 | 43 |
| Not completed | 6 | 7 | 2 | 5 | 8 | 2 | 7 |
| Withdrew: Withdrawal by subject | 3 | 5 | 2 | 1 | 4 | 0 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Subject unable to visit due to working out of town | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 2 | 1 | 0 | 4 | 1 | 2 | 0 |
| Withdrew: Inadvertent enrollment | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Subject could not tolerate investigational product (ip) and was taken off | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Patient was initially long term follow-up but contacted and came to site after follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
| Percent change | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Body Weight in LY3502970 and Placebo | -8.6 ± 0.85 | -11.2 ± 0.82 | -12.3 ± 0.77 | -12.6 ± 0.75 | -2.0 ± 0.81 |
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
| Percent change | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Body Weight in LY3502970 and Placebo | -9.4 ± 1.05 | -12.5 ± 1.01 | -13.5 ± 0.95 | -14.7 ± 0.94 | -2.3 ± 1.00 |
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
| kg | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Body Weight in LY3502970 and Placebo | -9.0 ± 0.90 | -12.3 ± 0.86 | -12.9 ± 0.82 | -13.3 ± 0.79 | -2.1 ± 0.86 |
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
| kg | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Body Weight in LY3502970 and Placebo | -9.8 ± 1.10 | -13.6 ± 1.06 | -14.2 ± 1.00 | -15.4 ± 0.98 | -2.4 ± 1.05 |
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
| centimeter (cm) | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Waist Circumference in LY3502970 and Placebo | -8.0 ± 1.03 | -8.8 ± 1.00 | -10.1 ± 0.94 | -12.2 ± 0.93 | -3.6 ± 0.99 |
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
| cm | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Waist Circumference in LY3502970 and Placebo | -9.6 ± 1.18 | -11.2 ± 1.15 | -10.6 ± 1.06 | -13.6 ± 1.07 | -4.0 ± 1.12 |
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
| kilograms per meter square (kg/m^2) | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in BMI in LY3502970 and Placebo | -3.2 ± 0.31 | -4.2 ± 0.30 | -4.6 ± 0.28 | -4.7 ± 0.27 | -0.8 ± 0.29 |
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
| kg/m^2 | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in BMI in LY3502970 and Placebo | -3.4 ± 0.38 | -4.7 ± 0.36 | -5.0 ± 0.34 | -5.5 ± 0.34 | -0.9 ± 0.36 |
Percentage of participants with \>=5% body weight loss was reported.
| percentage of participants | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With >=5% Body Weight Loss | 74.39 | 88.84 | 89.46 | 87.26 | 22.88 |
Percentage of participants with \>=10% body weight loss was reported.
| percentage of participants | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With >=10% Body Weight Loss | 39.39 | 56.61 | 71.30 | 69.86 | 2.25 |
Percentage of participants with \>=5% body weight loss was reported.
| percentage of participants | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With >=5% Body Weight Loss | 72.00 | 89.47 | 92.05 | 90.44 | 24.02 |
Percentage of participants with \>=10% body weight loss was reported.
| percentage of participants | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg LY3502970 | 45 mg LY3502970 | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With >=10% Body Weight Loss | 46.50 | 61.88 | 74.75 | 69.07 | 8.85 |
Collected over Baseline through Week 38 (36 weeks with 2 weeks safety follow up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 12 mg LY3502970 | 0/50 (0%) | 0/50 (0%) | 35/50 (70%) |
| 24 mg LY3502970 | 0/53 (0%) | 2/53 (3.8%) | 46/53 (86.8%) |
| 36 Mg-1 LY3502970 | 0/29 (0%) | 0/29 (0%) | 23/29 (79.3%) |
| 36 Mg-2 LY3502970 | 0/29 (0%) | 3/29 (10.3%) | 25/29 (86.2%) |
| 45 Mg-1 LY3502970 | 0/31 (0%) | 2/31 (6.5%) | 26/31 (83.9%) |
| 45 Mg-2 LY3502970 | 0/30 (0%) | 0/30 (0%) | 24/30 (80%) |
| Placebo | 0/50 (0%) | 0/50 (0%) | 27/50 (54%) |
| Event | 12 mg LY3502970 | 24 mg LY3502970 | 36 Mg-1 LY3502970 | 36 Mg-2 LY3502970 | 45 Mg-1 LY3502970 | 45 Mg-2 LY3502970 | Placebo |
|---|---|---|---|---|---|---|---|
| Retinal vein thrombosisEye disorders | 0/50 | 0/53 | 0/29 | 1/29 | 0/31 | 0/30 | 0/50 |
| Diverticulum intestinalGastrointestinal disorders | 0/50 | 0/53 | 0/29 | 1/29 | 0/31 | 0/30 | 0/50 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/50 | 0/53 | 0/29 | 1/29 | 0/31 | 0/30 | 0/50 |
| Hepatic cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 0/53 | 0/29 | 1/29 | 0/31 | 0/30 | 0/50 |
| Coronary artery diseaseCardiac disorders | 0/50 | 0/53 | 0/29 | 0/29 | 1/31 | 0/30 | 0/50 |
| Vitreoretinal traction syndromeEye disorders | 0/50 | 0/53 | 0/29 | 0/29 | 1/31 | 0/30 | 0/50 |
| Gastrointestinal polyp haemorrhageGastrointestinal disorders | 0/50 | 1/53 | 0/29 | 0/29 | 0/31 | 0/30 | 0/50 |
| Cholecystitis acuteHepatobiliary disorders | 0/50 | 1/53 | 0/29 | 0/29 | 0/31 | 0/30 | 0/50 |
| Event | 12 mg LY3502970 | 24 mg LY3502970 | 36 Mg-1 LY3502970 | 36 Mg-2 LY3502970 | 45 Mg-1 LY3502970 | 45 Mg-2 LY3502970 | Placebo |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 25/50 | 31/53 | 12/29 | 14/29 | 13/31 | 11/30 | 5/50 |
| DiarrhoeaGastrointestinal disorders | 12/50 | 19/53 | 1/29 | 4/29 | 5/31 | 10/30 | 5/50 |
| ConstipationGastrointestinal disorders | 12/50 | 17/53 | 8/29 | 7/29 | 6/31 | 4/30 | 3/50 |
| VomitingGastrointestinal disorders | 13/50 | 17/53 | 8/29 | 4/29 | 9/31 | 8/30 | 3/50 |
| Covid-19Infections and infestations | 9/50 | 9/53 | 4/29 | 7/29 | 5/31 | 5/30 | 9/50 |
| EructationGastrointestinal disorders | 9/50 | 11/53 | 5/29 | 2/29 | 2/31 | 6/30 | 0/50 |
| DyspepsiaGastrointestinal disorders | 8/50 | 4/53 | 1/29 | 1/29 | 3/31 | 2/30 | 3/50 |
| HeadacheNervous system disorders | 4/50 | 8/53 | 3/29 | 2/29 | 4/31 | 2/30 | 5/50 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 4/50 | 5/53 | 3/29 | 4/29 | 4/31 | 2/30 | 1/50 |
| FatigueGeneral disorders | 2/50 | 7/53 | 4/29 | 2/29 | 4/31 | 4/30 | 1/50 |
All randomized participants.
| Age, Continuous(years) | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg -1 LY3502970 | 36 mg -2 LY3502970 | 45 mg -1 LY3502970 | 45 mg -2 LY3502970 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 49.80 ± 10.51 | 57.00 ± 9.09 | 56.30 ± 11.83 | 55.40 ± 10.93 | 56.50 ± 10.74 | 50.90 ± 12.58 | 54.00 ± 8.82 | 54.20 ± 10.67 |
| Sex: Female, Male(Participants) | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg -1 LY3502970 | 36 mg -2 LY3502970 | 45 mg -1 LY3502970 | 45 mg -2 LY3502970 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 31 | 30 | 18 | 18 | 19 | 16 | 29 | 161 |
| Male | 19 | 23 | 11 | 11 | 12 | 14 | 21 | 111 |
| Ethnicity (NIH/OMB)(Participants) | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg -1 LY3502970 | 36 mg -2 LY3502970 | 45 mg -1 LY3502970 | 45 mg -2 LY3502970 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 6 | 4 | 2 | 4 | 7 | 5 | 39 |
| Not Hispanic or Latino | 38 | 46 | 23 | 26 | 25 | 22 | 43 | 223 |
| Unknown or Not Reported | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 10 |
| Race (NIH/OMB)(Participants) | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg -1 LY3502970 | 36 mg -2 LY3502970 | 45 mg -1 LY3502970 | 45 mg -2 LY3502970 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 6 | 4 | 4 | 1 | 0 | 1 | 19 |
| White | 47 | 46 | 25 | 25 | 29 | 30 | 45 | 247 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg -1 LY3502970 | 36 mg -2 LY3502970 | 45 mg -1 LY3502970 | 45 mg -2 LY3502970 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Canada | 9 | 11 | 5 | 3 | 9 | 5 | 6 | 48 |
| Hungary | 6 | 5 | 3 | 6 | 3 | 3 | 5 | 31 |
| United States | 35 | 37 | 21 | 20 | 19 | 22 | 39 | 193 |
| Baseline Body Weight(Kilograms (kg)) | 12 mg LY3502970 | 24 mg LY3502970 | 36 mg -1 LY3502970 | 36 mg -2 LY3502970 | 45 mg -1 LY3502970 | 45 mg -2 LY3502970 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 107.49 ± 25.34 | 112.05 ± 30.18 | 107.78 ± 22.45 | 108.84 ± 28.52 | 105.23 ± 20.40 | 110.85 ± 28.11 | 107.57 ± 25.24 | 108.68 ± 26.03 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2021 to primary completion in Aug 2022, 10 months.
Results were first posted in Sep 2023, 1 year after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 10 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron